<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38675888</PMID><DateCompleted><Year>2024</Year><Month>04</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Mar</Month><Day>30</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Fluoxetine and Sertraline Potently Neutralize the Replication of Distinct SARS-CoV-2 Variants.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">545</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16040545</ELocationID><Abstract><AbstractText>The pandemic caused by SARS-CoV-2 is still a major health problem. Newly emerging variants and long-COVID-19 represent a challenge for the global health system. In particular, individuals in developing countries with insufficient health care need easily accessible, affordable and effective treatments of COVID-19. Previous studies have demonstrated the efficacy of functional inhibitors of acid sphingomyelinase against infections with various viruses, including early variants of SARS-CoV-2. This work investigated whether the acid sphingomyelinase inhibitors fluoxetine and sertraline, usually used as antidepressant molecules in clinical practice, can inhibit the replication of the former and recently emerged SARS-CoV-2 variants in vitro. Fluoxetine and sertraline potently inhibited the infection with pseudotyped virus-like particles and SARS-CoV-2 variants D614G, alpha, delta, omicron BA.1 and omicron BA.5. These results highlight fluoxetine and sertraline as priority candidates for large-scale phase 3 clinical trials at different stages of SARS-CoV-2 infections, either alone or in combination with other medications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Th&#xfc;mmler</LastName><ForeName>Laura</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-2034-6255</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, West German Centre of Infectious Diseases, University Medicine Essen, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Transfusion Medicine, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beckmann</LastName><ForeName>Nadine</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute of Molecular Biology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sehl</LastName><ForeName>Carolin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Molecular Biology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soddemann</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Molecular Biology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bra&#xdf;</LastName><ForeName>Peer</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-3169-9515</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, West German Centre of Infectious Diseases, University Medicine Essen, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bormann</LastName><ForeName>Maren</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0955-1453</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, West German Centre of Infectious Diseases, University Medicine Essen, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brochhagen</LastName><ForeName>Leonie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, West German Centre of Infectious Diseases, University Medicine Essen, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elsner</LastName><ForeName>Carina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute for Virology, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoertel</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute Psychiatry and Neuroscience de Paris, INSERM U1266, Paris Cit&#xe9; University, 75014 Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Psychiatry and Addiction Department Corentin-Celton Hospital (AP-HP), 92130 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cougoule</LastName><ForeName>C&#xe9;line</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-6795-5448</Identifier><AffiliationInfo><Affiliation>Institute of Pharmacology and Structural Biology (IPBS), CNRS, University of Toulouse, UPS, 31000 Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciesek</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Medical Virology, University Hospital Frankfurt, 60590 Frankfurt am Main, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Pharmaceutical Biology, Goethe-University, 60323 Frankfurt am Main, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Branch Translational Medicine and Pharmacology, 60311 Frankfurt am Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Widera</LastName><ForeName>Marek</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Medical Virology, University Hospital Frankfurt, 60590 Frankfurt am Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dittmer</LastName><ForeName>Ulf</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Institute for Virology, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindemann</LastName><ForeName>Monika</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6708-4390</Identifier><AffiliationInfo><Affiliation>Institute for Transfusion Medicine, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horn</LastName><ForeName>Peter A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Institute for Transfusion Medicine, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Witzke</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, West German Centre of Infectious Diseases, University Medicine Essen, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kadow</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-6430-1230</Identifier><AffiliationInfo><Affiliation>Institute of Molecular Biology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamler</LastName><ForeName>Markus</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6608-8496</Identifier><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, West German Heart Center, University Hospital Essen, 45147 Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gulbins</LastName><ForeName>Erich</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute of Molecular Biology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>Katrin Anne</ForeName><Initials>KA</Initials><Identifier Source="ORCID">0000-0002-6317-7298</Identifier><AffiliationInfo><Affiliation>Institute of Molecular Biology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krawczyk</LastName><ForeName>Adalbert</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9502-9903</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, West German Centre of Infectious Diseases, University Medicine Essen, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Virology, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>QUC7NX6WMB</RegistryNumber><NameOfSubstance UI="D020280">Sertraline</NameOfSubstance></Chemical><Chemical><RegistryNumber>01K63SUP8D</RegistryNumber><NameOfSubstance UI="D005473">Fluoxetine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020280" MajorTopicYN="Y">Sertraline</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005473" MajorTopicYN="Y">Fluoxetine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="Y">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antidepressants</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>3</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>27</Day><Hour>9</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>27</Day><Hour>9</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>27</Day><Hour>1</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38675888</ArticleId><ArticleId IdType="pmc">PMC11053511</ArticleId><ArticleId IdType="doi">10.3390/v16040545</ArticleId><ArticleId IdType="pii">v16040545</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Worldometers.  [(accessed on 8 January 2024)].  Available online:  https://www.worldometers.info/coronavirus/</Citation></Reference><Reference><Citation>Panneer S., Kantamaneni K., Akkayasamy V.S., Susairaj A.X., Panda P.K., Acharya S.S., Rice L., Liyanage C., Pushparaj R.R.B. The Great Lockdown in the Wake of COVID-19 and Its Implications: Lessons for Low and Middle-Income Countries. Int. J. Environ. Res. Public Health. 2022;19:610. doi: 10.3390/ijerph19010610.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph19010610</ArticleId><ArticleId IdType="pmc">PMC8744631</ArticleId><ArticleId IdType="pubmed">35010863</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamm T.A., Partheym&#xfc;ller J., Mosor E., Ritschl V., Kritzinger S., Alunno A., Eberl J.-M. Determinants of COVID-19 vaccine fatigue. Nat. Med. 2023;29:1164&#x2013;1171. doi: 10.1038/s41591-023-02282-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-023-02282-y</ArticleId><ArticleId IdType="pmc">PMC10202806</ArticleId><ArticleId IdType="pubmed">36973410</ArticleId></ArticleIdList></Reference><Reference><Citation>Bormann M., Brochhagen L., Alt M., Otte M., Th&#xfc;mmler L., van de Sand L., Kraiselburd I., Thomas A., Gosch J., Bra&#xdf; P., et al. Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5. Front. Immunol. 2023;14:1150667. doi: 10.3389/fimmu.2023.1150667.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1150667</ArticleId><ArticleId IdType="pmc">PMC10372796</ArticleId><ArticleId IdType="pubmed">37520539</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergwerk M., Gonen T., Lustig Y., Amit S., Lipsitch M., Cohen C., Mandelboim M., Levin E.G., Rubin C., Indenbaum V., et al. Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. N. Engl. J. Med. 2021;385:1474&#x2013;1484. doi: 10.1056/NEJMoa2109072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2109072</ArticleId><ArticleId IdType="pmc">PMC8362591</ArticleId><ArticleId IdType="pubmed">34320281</ArticleId></ArticleIdList></Reference><Reference><Citation>Dash N.R., Barqawi H.J., Obaideen A.A., Al Chame H.Q., Samara K.A., Qadri R., Eldesouki S. COVID-19 Breakthrough Infection Among Vaccinated Population in the United Arab Emirates. J. Epidemiol. Glob. Health. 2023;13:67&#x2013;90. doi: 10.1007/s44197-023-00090-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s44197-023-00090-8</ArticleId><ArticleId IdType="pmc">PMC9933808</ArticleId><ArticleId IdType="pubmed">36795274</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Wu Y., Chen S., Zhan Q., Wu D., Yang C., He X., Qiu M., Zhang N., Li Z., et al. Sertraline Is an Effective SARS-CoV-2 Entry Inhibitor Targeting the Spike Protein. J. Virol. 2022;96:e01245-22. doi: 10.1128/jvi.01245-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.01245-22</ArticleId><ArticleId IdType="pmc">PMC9769394</ArticleId><ArticleId IdType="pubmed">36468859</ArticleId></ArticleIdList></Reference><Reference><Citation>Manganaro R., Zonsics B., Bauer L., Lopez M.L., Donselaar T., Zwaagstra M., Saporito F., Ferla S., Strating J.R.P.M., Coutard B., et al. Synthesis and antiviral effect of novel fluoxetine analogues as enterovirus 2C inhibitors. Antivir. Res. 2020;178:104781. doi: 10.1016/j.antiviral.2020.104781.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2020.104781</ArticleId><ArticleId IdType="pubmed">32234539</ArticleId></ArticleIdList></Reference><Reference><Citation>Messacar K., Sillau S., Hopkins S.E., Otten C., Wilson-Murphy M., Wong B., Santoro J.D., Treister A., Bains H.K., Torres A., et al. Safety, tolerability, and efficacy of fluoxetine as an antiviral for acute flaccid myelitis. Neurology. 2019;92:E2118&#x2013;E2126. doi: 10.1212/WNL.0000000000006670.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006670</ArticleId><ArticleId IdType="pmc">PMC6512883</ArticleId><ArticleId IdType="pubmed">30413631</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng K.C., Hsu B.Y., Ling P., Lu W.W., Lin C.W., Kung S.H. Antidepressant Sertraline Is a Broad-Spectrum Inhibitor of Enteroviruses Targeting Viral Entry through Neutralization of Endolysosomal Acidification. Viruses. 2022;14:109. doi: 10.3390/v14010109.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14010109</ArticleId><ArticleId IdType="pmc">PMC8780434</ArticleId><ArticleId IdType="pubmed">35062313</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo J., Quinn K.K., Kye S., Cooper P., Damoiseaux R., Krogstad P. Fluoxetine Is a Potent Inhibitor of Coxsackievirus Replication. Antimicrob. Agents Chemother. 2012;56:4838&#x2013;4844. doi: 10.1128/AAC.00983-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00983-12</ArticleId><ArticleId IdType="pmc">PMC3421851</ArticleId><ArticleId IdType="pubmed">22751539</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel K., Lim S.G., Cheng C.W., Lawitz E., Tillmann H.L., Chopra N., Altmeyer R., Randle J.C.R., McHutchison J.G. Open-label Phase 1b pilot study to assess the antiviral efficacy of simvastatin combined with sertraline in chronic hepatitis C patients. Antivir. Ther. 2011;16:1341&#x2013;1346. doi: 10.3851/IMP1898.</Citation><ArticleIdList><ArticleId IdType="doi">10.3851/IMP1898</ArticleId><ArticleId IdType="pubmed">22155916</ArticleId></ArticleIdList></Reference><Reference><Citation>Herring S., Oda J.M., Wagoner J., Kirchmeier D., O&#x2019;Connor A., Nelson E.A., Huang Q.F., Liang Y.Y., DeWald L.E., Johansen L.M., et al. Inhibition of Arenaviruses by Combinations of Orally Available Approved Drugs. Antimicrob. Agents Chemother. 2021;65:e01146-20. doi: 10.1128/AAC.01146-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01146-20</ArticleId><ArticleId IdType="pmc">PMC8097473</ArticleId><ArticleId IdType="pubmed">33468464</ArticleId></ArticleIdList></Reference><Reference><Citation>Albouz S., Boutry J.M., Dubois G., Bourdon R., Hauw J.J., Baumann N. Lipid and lysosomal enzymes in human fibroblasts cultured with perhexiline maleate. Naunyn-Schmiedebergs Arch. Pharmacol. 1981;317:173&#x2013;177. doi: 10.1007/BF00500076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00500076</ArticleId><ArticleId IdType="pubmed">7300921</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurwitz R., Ferlinz K., Sandhoff K. The Tricyclic Antidepressant Desipramine Causes Proteolytic Degradation of Lysosomal Sphingomyelinase in Human Fibroblasts. Biol. Chem. Hoppe-Seyler. 1994;375:447&#x2013;450. doi: 10.1515/bchm3.1994.375.7.447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/bchm3.1994.375.7.447</ArticleId><ArticleId IdType="pubmed">7945993</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornhuber J., Tripal P., Reichel M., M&#xfc;hle C., Rhein C., Muehlbacher M., Groemer T.W., Gulbins E. Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): A novel pharmacological group of drugs with broad clinical applications. Cell Physiol. Biochem. 2010;26:9&#x2013;20. doi: 10.1159/000315101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000315101</ArticleId><ArticleId IdType="pubmed">20502000</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimniak M., Kirschner L., Hilpert H., Geiger N., Danov O., Oberwinkler H., Steinke M., Sewald K., Seibel J., Bodem J. The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue. Sci. Rep. 2021;11:5890. doi: 10.1038/s41598-021-85049-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-85049-0</ArticleId><ArticleId IdType="pmc">PMC7961020</ArticleId><ArticleId IdType="pubmed">33723270</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutkat O., Moatasim Y., Al-Karmalawy A.A., Abulkhair H.S., Gomaa M.R., El-Taweel A.N., Abo Shama N.M., GabAllah M., Mahmoud D.B., Kayali G., et al. Robust antiviral activity of commonly prescribed antidepressants against emerging coronaviruses: In vitro and in silico drug repurposing studies. Sci. Rep. 2022;12:12920. doi: 10.1038/s41598-022-17082-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-17082-6</ArticleId><ArticleId IdType="pmc">PMC9331004</ArticleId><ArticleId IdType="pubmed">35902647</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;ricat D., Leon-Icaza S.A., Sanchez Rico M., M&#xfc;hle C., Zoicas I., Schumacher F., Plan&#xe8;s R., Mazars R., Gros G., Carpinteiro A., et al. Antiviral and Anti-Inflammatory Activities of Fluoxetine in a SARS-CoV-2 Infection Mouse Model. Int. J. Mol. Sci. 2022;23:13623. doi: 10.3390/ijms232113623.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms232113623</ArticleId><ArticleId IdType="pmc">PMC9657171</ArticleId><ArticleId IdType="pubmed">36362409</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenze E.J., Mattar C., Zorumski C.F., Stevens A., Schweiger J., Nicol G.E., Miller J.P., Yang L., Yingling M., Avidan M.S., et al. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients with Symptomatic COVID-19: A Randomized Clinical Trial. JAMA. 2020;324:2292&#x2013;2300. doi: 10.1001/jama.2020.22760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.22760</ArticleId><ArticleId IdType="pmc">PMC7662481</ArticleId><ArticleId IdType="pubmed">33180097</ArticleId></ArticleIdList></Reference><Reference><Citation>Calusic M., Marcec R., Luksa L., Jurkovic I., Kovac N., Mihaljevic S., Likic R. Safety and efficacy of fluvoxamine in COVID-19 ICU patients: An open label, prospective cohort trial with matched controls. Br. J. Clin. Pharmacol. 2022;88:2065&#x2013;2073. doi: 10.1111/bcp.15126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.15126</ArticleId><ArticleId IdType="pmc">PMC8653355</ArticleId><ArticleId IdType="pubmed">34719789</ArticleId></ArticleIdList></Reference><Reference><Citation>Seftel D., Boulware D.R. Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19. Open Forum. Infect. Dis. 2021;8:ofab050. doi: 10.1093/ofid/ofab050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab050</ArticleId><ArticleId IdType="pmc">PMC7888564</ArticleId><ArticleId IdType="pubmed">33623808</ArticleId></ArticleIdList></Reference><Reference><Citation>Reis G., Silva E., Silva D.C.M., Thabane L., Milagres A.C., Ferreira T.S., Dos Santos C.V.Q., Campos V.H.S., Nogueira A.M.R., de Almeida A., et al. Effect of Early Treatment with Ivermectin among Patients with COVID-19. N. Engl. J. Med. 2022;386:1721&#x2013;1731. doi: 10.1056/NEJMoa2115869.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2115869</ArticleId><ArticleId IdType="pmc">PMC9006771</ArticleId><ArticleId IdType="pubmed">35353979</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpinteiro A., Edwards M.J., Hoffmann M., Kochs G., Gripp B., Weigang S., Adams C., Carpinteiro E., Gulbins A., Keitsch S., et al. Pharmacological Inhibition of Acid Sphingomyelinase Prevents Uptake of SARS-CoV-2 by Epithelial Cells. Cell Rep. Med. 2020;1:100142. doi: 10.1016/j.xcrm.2020.100142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2020.100142</ArticleId><ArticleId IdType="pmc">PMC7598530</ArticleId><ArticleId IdType="pubmed">33163980</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpinteiro A., Gripp B., Hoffmann M., P&#xf6;hlmann S., Hoertel N., Edwards M.J., Kamler M., Kornhuber J., Becker K.A., Gulbins E. Inhibition of acid sphingomyelinase by ambroxol prevents SARS-CoV-2 entry into epithelial cells. J. Biol. Chem. 2021;296:100701. doi: 10.1016/j.jbc.2021.100701.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2021.100701</ArticleId><ArticleId IdType="pmc">PMC8062550</ArticleId><ArticleId IdType="pubmed">33895135</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoertel N. Do the Selective Serotonin Reuptake Inhibitor Antidepressants Fluoxetine and Fluvoxamine Reduce Mortality among Patients with COVID-19? JAMA Netw. Open. 2021;4:e2136510. doi: 10.1001/jamanetworkopen.2021.36510.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.36510</ArticleId><ArticleId IdType="pubmed">34779851</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoertel N., S&#xe1;nchez-Rico M., Cougoule C., Gulbins E., Kornhuber J., Carpinteiro A., Becker K.A., Reiersen A.M., Lenze E.J., Seftel D., et al. Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: Current evidence and potential mechanisms. Mol. Psychiatry. 2021;26:7098&#x2013;7099. doi: 10.1038/s41380-021-01254-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-021-01254-3</ArticleId><ArticleId IdType="pmc">PMC8359627</ArticleId><ArticleId IdType="pubmed">34385600</ArticleId></ArticleIdList></Reference><Reference><Citation>Widera M., Wilhelm A., Toptan T., Raffel J.M., Kowarz E., Roesmann F., Grozinger F., Siemund A.L., Luciano V., Kulp M., et al. Generation of a Sleeping Beauty Transposon-Based Cellular System for Rapid and Sensitive Screening for Compounds and Cellular Factors Limiting SARS-CoV-2 Replication. Front. Microbiol. 2021;12:701198. doi: 10.3389/fmicb.2021.701198.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.701198</ArticleId><ArticleId IdType="pmc">PMC8362758</ArticleId><ArticleId IdType="pubmed">34394046</ArticleId></ArticleIdList></Reference><Reference><Citation>Th&#xfc;mmler L., G&#xe4;ckler A., Bormann M., Ciesek S., Widera M., Rohn H., Fisenkci N., Otte M., Alt M., Dittmer U., et al. Cellular and Humoral Immunity against Different SARS-CoV-2 Variants Is Detectable but Reduced in Vaccinated Kidney Transplant Patients. Vaccines. 2022;10:1348. doi: 10.3390/vaccines10081348.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10081348</ArticleId><ArticleId IdType="pmc">PMC9412329</ArticleId><ArticleId IdType="pubmed">36016235</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO.  [(accessed on 9 January 2024)].  Available online:  https://www.who.int/activities/tracking-SARS-CoV-2-variants.</Citation></Reference><Reference><Citation>Heilingloh C.S., Aufderhorst U.W., Schipper L., Dittmer U., Witzke O., Yang D., Zheng X., Sutter K., Trilling M., Alt M., et al. Susceptibility of SARS-CoV-2 to UV irradiation. Am. J. Infect. Control. 2020;48:1273&#x2013;1275. doi: 10.1016/j.ajic.2020.07.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajic.2020.07.031</ArticleId><ArticleId IdType="pmc">PMC7402275</ArticleId><ArticleId IdType="pubmed">32763344</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M., Kleine-Weber H., Schroeder S., Kr&#xfc;ger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A., et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181:271&#x2013;280.e278. doi: 10.1016/j.cell.2020.02.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger Rentsch M., Zimmer G. A vesicular stomatitis virus replicon-based bioassay for the rapid and sensitive determination of multi-species type I interferon. PLoS ONE. 2011;6:e25858. doi: 10.1371/journal.pone.0025858.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0025858</ArticleId><ArticleId IdType="pmc">PMC3187809</ArticleId><ArticleId IdType="pubmed">21998709</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker K.A., Carpinteiro A., Hoffmann M., P&#xf6;hlmann S., Kornhuber J., Gulbins E. Ex vivo assay to evaluate the efficacy of drugs targeting sphingolipids in preventing SARS-CoV-2 infection of nasal epithelial cells. STAR Protoc. 2021;2:100356. doi: 10.1016/j.xpro.2021.100356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xpro.2021.100356</ArticleId><ArticleId IdType="pmc">PMC7857112</ArticleId><ArticleId IdType="pubmed">33558862</ArticleId></ArticleIdList></Reference><Reference><Citation>Zettl F., Meister T.L., Vollmer T., Fischer B., Steinmann J., Krawczyk A., V&#x2019;kovski P., Todt D., Steinmann E., Pfaender S., et al. Rapid Quantification of SARS-CoV-2-Neutralizing Antibodies Using Propagation-Defective Vesicular Stomatitis Virus Pseudotypes. Vaccines. 2020;8:386. doi: 10.3390/vaccines8030386.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines8030386</ArticleId><ArticleId IdType="pmc">PMC7563800</ArticleId><ArticleId IdType="pubmed">32679691</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M., Hofmann-Winkler H., Kr&#xfc;ger N., Kempf A., Nehlmeier I., Graichen L., Arora P., Sidarovich A., Moldenhauer A.S., Winkler M.S., et al. SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination. Cell Rep. 2021;36:109415. doi: 10.1016/j.celrep.2021.109415.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109415</ArticleId><ArticleId IdType="pmc">PMC8238662</ArticleId><ArticleId IdType="pubmed">34270919</ArticleId></ArticleIdList></Reference><Reference><Citation>Fred S.M., Kuivanen S., Ugurlu H., Casarotto P.C., Levanov L., Saksela K., Vapalahti O., Castr&#xe9;n E. Antidepressant and Antipsychotic Drugs Reduce Viral Infection by SARS-CoV-2 and Fluoxetine Shows Antiviral Activity Against the Novel Variants in vitro. Front. Pharmacol. 2021;12:755600. doi: 10.3389/fphar.2021.755600.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.755600</ArticleId><ArticleId IdType="pmc">PMC8809408</ArticleId><ArticleId IdType="pubmed">35126106</ArticleId></ArticleIdList></Reference><Reference><Citation>Geiger N., Kersting L., Schlegel J., Stelz L., F&#xe4;hr S., Diesendorf V., Roll V., Sostmann M., K&#xf6;nig E.-M., Reinhard S., et al. The Acid Ceramidase Is a SARS-CoV-2 Host Factor. Cells. 2022;11:2532. doi: 10.3390/cells11162532.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11162532</ArticleId><ArticleId IdType="pmc">PMC9406565</ArticleId><ArticleId IdType="pubmed">36010608</ArticleId></ArticleIdList></Reference><Reference><Citation>Schloer S., Brunotte L., Goretzko J., Mecate-Zambrano A., Korthals N., Gerke V., Ludwig S., Rescher U. Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine. Emerg. Microbes Infect. 2020;9:2245&#x2013;2255. doi: 10.1080/22221751.2020.1829082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1829082</ArticleId><ArticleId IdType="pmc">PMC7594754</ArticleId><ArticleId IdType="pubmed">32975484</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornhuber J., Hoertel N., Gulbins E. The acid sphingomyelinase/ceramide system in COVID-19. Mol. Psychiatry. 2022;27:307&#x2013;314. doi: 10.1038/s41380-021-01309-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-021-01309-5</ArticleId><ArticleId IdType="pmc">PMC8488928</ArticleId><ArticleId IdType="pubmed">34608263</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xf6;rnquist K., Asghar M.Y., Srinivasan V., Korhonen L., Lindholm D. Sphingolipids as Modulators of SARS-CoV-2 Infection. Front. Cell Dev. Biol. 2021;9:689854. doi: 10.3389/fcell.2021.689854.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.689854</ArticleId><ArticleId IdType="pmc">PMC8245774</ArticleId><ArticleId IdType="pubmed">34222257</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckmann N., Becker K.A. Ceramide and Related Molecules in Viral Infections. Int. J. Mol. Sci. 2021;22:5676. doi: 10.3390/ijms22115676.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22115676</ArticleId><ArticleId IdType="pmc">PMC8197834</ArticleId><ArticleId IdType="pubmed">34073578</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto Y., Suzuki T., Hashimoto K. Mechanisms of action of fluvoxamine for COVID-19: A historical review. Mol. Psychiatry. 2022;27:1898&#x2013;1907. doi: 10.1038/s41380-021-01432-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-021-01432-3</ArticleId><ArticleId IdType="pmc">PMC8739627</ArticleId><ArticleId IdType="pubmed">34997196</ArticleId></ArticleIdList></Reference><Reference><Citation>Grassme H., Riehle A., Wilker B., Gulbins E. Rhinoviruses infect human epithelial cells via ceramide-enriched membrane platforms. J. Biol. Chem. 2005;280:26256&#x2013;26262. doi: 10.1074/jbc.M500835200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M500835200</ArticleId><ArticleId IdType="pubmed">15888438</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller M.E., Adhikary S., Kolokoltsov A.A., Davey R.A. Ebolavirus requires acid sphingomyelinase activity and plasma membrane sphingomyelin for infection. J. Virol. 2012;86:7473&#x2013;7483. doi: 10.1128/JVI.00136-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00136-12</ArticleId><ArticleId IdType="pmc">PMC3416309</ArticleId><ArticleId IdType="pubmed">22573858</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoertel N., Rezaei K., S&#xe1;nchez-Rico M., Delgado-&#xc1;lvarez A., Kornhuber J., Gulbins E., Olfson M., Ouazana-Vedrines C., Carpinteiro A., Cougoule C., et al. Medications Modulating the Acid Sphingomyelinase/Ceramide System and 28-Day Mortality among Patients with SARS-CoV-2: An Observational Study. Pharmaceuticals. 2023;16:1107. doi: 10.3390/ph16081107.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph16081107</ArticleId><ArticleId IdType="pmc">PMC10458150</ArticleId><ArticleId IdType="pubmed">37631022</ArticleId></ArticleIdList></Reference><Reference><Citation>Reis G., Dos Santos Moreira Silva E.A., Medeiros Silva D.C., Thabane L., de Souza Campos V.H., Ferreira T.S., Quirino Dos Santos C.V., Ribeiro Nogueira A.M., Figueiredo Guimaraes Almeida A.P., Can&#xe7;ado Monteiro Savassi L., et al. Oral Fluvoxamine with Inhaled Budesonide for Treatment of Early-Onset COVID-19: A Randomized Platform Trial. Ann. Intern. Med. 2023;176:667&#x2013;675. doi: 10.7326/M22-3305.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M22-3305</ArticleId><ArticleId IdType="pmc">PMC10111398</ArticleId><ArticleId IdType="pubmed">37068273</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Wei Y., Hung C.T., Jiang X., Li C., Jia K.M., Leung E.Y.M., Yam C.H.K., Chow T.Y., Zhao S., et al. Relationship between antidepressants and severity of SARS-CoV-2 Omicron infection: A retrospective cohort study using real-world data. Lancet Reg. Health West. Pac. 2023;34:100716. doi: 10.1016/j.lanwpc.2023.100716.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanwpc.2023.100716</ArticleId><ArticleId IdType="pmc">PMC9970034</ArticleId><ArticleId IdType="pubmed">37256206</ArticleId></ArticleIdList></Reference><Reference><Citation>Jittamala P., Boyd S., Schilling W.H., Watson J.A., Ngamprasertchai T., Siripoon T., Luvira V., Batty E.M., Wongnak P., Esper L.M., et al. Antiviral efficacy of fluoxetine in early symptomatic COVID-19: An open-label, randomised, controlled, adaptive platform trial (PLATCOV) medRxiv. 2024 doi: 10.1101/2024.01.16.24301337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2024.01.16.24301337</ArticleId><ArticleId IdType="pmc">PMC10789040</ArticleId><ArticleId IdType="pubmed">38225598</ArticleId></ArticleIdList></Reference><Reference><Citation>Reis G., Dos Santos Moreira-Silva E.A., Silva D.C.M., Thabane L., Milagres A.C., Ferreira T.S., Dos Santos C.V.Q., de Souza Campos V.H., Nogueira A.M.R., de Almeida A., et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: The TOGETHER randomised, platform clinical trial. Lancet Glob. Health. 2022;10:e42&#x2013;e51. doi: 10.1016/S2214-109X(21)00448-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(21)00448-4</ArticleId><ArticleId IdType="pmc">PMC8550952</ArticleId><ArticleId IdType="pubmed">34717820</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskotsky T., Maric I., Tang A., Oskotsky B., Wong R.J., Aghaeepour N., Sirota M., Stevenson D.K. Mortality Risk Among Patients with COVID-19 Prescribed Selective Serotonin Reuptake Inhibitor Antidepressants. JAMA Netw Open. 2021;4:e2133090. doi: 10.1001/jamanetworkopen.2021.33090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.33090</ArticleId><ArticleId IdType="pmc">PMC8593759</ArticleId><ArticleId IdType="pubmed">34779847</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>